Mineralys Therapeutics CMO Rodman Executes Pre-Arranged Stock Sale and Option Exercise
David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics (NASDAQ: MLYS), executed a series of transactions on July 9, 2026, involving the sale of 2,171 shares and the exercise of an equivalent number of stock options. The sale, conducted under a pre-established Rule 10b5-1 trading plan, resulted in proceeds of $65,781 at a price of $30.…